ZENO MANAGEMENT, INC
Biotech
Novel ERK inhibitor molecules for KRAS-mutant pancreatic cancer treatment
- Grants
- $1.9M
- 2 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 1 granted · 39 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | $1,060,799 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | $856,578 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2388 | Avalo Therapeutics | — | $182M |
| 2389 | MOCKV SOLUTIONS INC. | — | — |
| 2390 | SERPIN PHARMA, LLC | — | — |
| 2391 | ZENO MANAGEMENT, INC | — | — |
| 2392 | CH3 BIOSYSTEMS, LLC | — | — |
| 2393 | Autifony Therapeutics | — | — |
| 2394 | EXARCA PHARMACEUTICALS, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Alteration Of F-box And Wd Repeat Domain Containing 7 (FBXW7) Gene As A Predictive Biomarker For Treating Cancer With WEE1 Inhibitorsapplication
- Solid Forms Of A WEE1 Inhibitorapplication
- Homologous Recombination Repair Deficiency (hrd) As A Predictive Biomarker For Treating Cancer With WEE1 Inhibitorsapplication
- Intermittent Dosing Regimen For Azenosertib In Treating Cancerapplication
- Use Of Cyclin E1 Status As A Predictive Biomarker For Treating Cancer With WEE1 Inhibitorsapplication
- Immunoconjugates And Methodsgranted
- Macrocyclic Compoundsapplication
- Macrocyclic Compoundsapplication
- WEE1 Inhibitor Combination Therapyapplication
- Alteration Of F-box And Wd Repeat Domain Containing 7 (FBXW7) Gene As A Predictive Biomarker For Treating Cancer With WEE1 Inhibitorsapplication
- Bi-cyclic Pyrimidine Compounds, Methods And Uses Thereofapplication
- Solid Forms Of A WEE1 Inhibitorapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.